Clinical trial
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
NCT00263965 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00263965 |
|---|---|
| Title | ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity |
| Official title | A 16-Week Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo- and Active- (Metformin) Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Behavioral, Drug |
| Interventions | Tesaglitazar, Metformin, Dietary and lifestyle modification counseling |
| Enrollment | 105 |
| Start date | Aug 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Dec 12, 2005 |
| Last update posted | Mar 17, 2008 |
| Countries | Finland, Italy, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: